Show simple item record

dc.contributor.authorPavel, M
dc.contributor.authorGross, D
dc.contributor.authorBenavent, M
dc.contributor.authorCaplin, M
dc.contributor.authorPerros, P
dc.contributor.authorSrirajaskanthan, R
dc.contributor.authorValle, Juan W
dc.contributor.authorWarner, R
dc.contributor.authorKulke, M
dc.contributor.authorAnthony, L
dc.contributor.authorKunz, P
dc.contributor.authorHorsch, D
dc.contributor.authorBerg, K
dc.contributor.authorLapuerta, P
dc.contributor.authorJackson, S
dc.contributor.authorBanks, P
dc.contributor.authorBiran, T
dc.contributor.authorGarcia-Carbonero, R
dc.date.accessioned2017-05-19T15:32:24Z
dc.date.available2017-05-19T15:32:24Z
dc.date.issued2017
dc.identifier.citationEfficacy and safety results of telotristat ethyl in patients With carcinoid syndrome during the double-blind treatment period of the TELECAST phase 3 clinical trial. 2017, 46(3): 434-435 Pancreasen
dc.identifier.urihttp://hdl.handle.net/10541/620380
dc.language.isoenen
dc.titleEfficacy and safety results of telotristat ethyl in patients With carcinoid syndrome during the double-blind treatment period of the TELECAST phase 3 clinical trial.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentCharité-Universitätsmedizin Berlin, CVK, Med. Klinik m. Schwerpunkten
dc.identifier.journalPancreasen


This item appears in the following Collection(s)

Show simple item record